ORIC Pharmaceuticals, Inc. ORIC
Updated: 18 Jun 2026
No signal published yet
We already track ORIC Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow ORIC Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow ORIC Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 12, 2026, Stifel resumed coverage of the company with a Buy rating ahead of a planned Phase 3 trial for its lead candidate, rinzimetostat. In May 2026, the company reported a cash position of approximately $282 million, which is expected to fund operations into 2028. ORIC is currently preparing for multiple clinical data readouts across its programs over the next 18 months.
What Firelda Watch includes for ORIC Pharmaceuticals, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow ORIC Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow ORIC Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more